We recently published a list of 10 Best Performing Growth Stocks in 2025 In this article, we are going to take a look at ...

Tempus AI, Inc. TEM recently announced the acquisition of Deep 6 AI, a leading artificial intelligence (AI) company ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

In the article appearing in the AACR Journal, researchers at the Henry Ford Health Pancreatic Cancer Center, found that Black ...

Tempus is a cancer diagnostics company that provides genomic testing results. Tempus has also amassed an over 200 petabyte proprietary multimodal dataset that combines clinical patient data with ...

Artera and Tempus are collaborating to expand access to Artera’s AI-based prostate cancer test. Currently connected to more than 50% of all oncologists practising in the US, Chicago-based Tempus ...

Tempus will now offer the ArteraAI Prostate Test to cancer centers across the U.S. Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests ...

Tempus AI (TEM) announced it has acquired Deep 6 AI. Deep 6 AI enables healthcare organizations to de-risk clinical trials, accelerate ...

Before the acquisition, Ambry served as Tempus' largest reference laboratory for hereditary cancer screening, and the companies had entered a strategic collaboration to provide a combined ...

Ataraxis AI, the leading AI precision medicine company, today announced its $20.4 million Series A financing led by AIX ...

SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, and Tempus, a technology company leading the ...

Deep 6 is integrated with over 750 provider site locations spanning more than 30 million patients, which will materially add to Tempus’ existing ... National Cancer Institute (NCI)-Designated ...